2.88
-0.03(-1.03%)
Currency In USD
| Previous Close | 2.91 |
| Open | 2.9 |
| Day High | 2.91 |
| Day Low | 2.81 |
| 52-Week High | 135.54 |
| 52-Week Low | 2.75 |
| Volume | 52,594 |
| Average Volume | 1.64M |
| Market Cap | 2.31M |
| PE | 0 |
| EPS | -1,210.59 |
| Moving Average 50 Days | 4.27 |
| Moving Average 200 Days | 9.5 |
| Change | -0.03 |
If you invested $1000 in Alzamend Neuro, Inc. (ALZN) since IPO date, it would be worth $0.16 as of July 01, 2025 at a share price of $2.88. Whereas If you bought $1000 worth of Alzamend Neuro, Inc. (ALZN) shares 3 years ago, it would be worth $2.44 as of July 01, 2025 at a share price of $2.88.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
GlobeNewswire Inc.
Jun 16, 2025 12:00 PM GMT
Capital Raised to Support Five Clinical TrialsATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheime
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
GlobeNewswire Inc.
May 29, 2025 12:00 PM GMT
Massachusetts General Hospital Main Entrance Massachusetts General Hospital Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/br
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
GlobeNewswire Inc.
May 19, 2025 12:00 PM GMT
Massachusetts General Hospital Main Entrance Massachusetts General Hospital Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/br